Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 5/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.42 |
| ▸ | ESR1 | P03372 | 1/20 | 0.42 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.42 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.39 |
| ▸ | BRAF | P15056 | 4/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.37 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6721985 | 0.88 | ESR1 (0.55) | PTGS2PTGS1ESR1ESR2ALOX5 | |
| SCHEMBL6734030 | 0.87 | PTGS2 (0.41) | PTGS2PTGS1ESR1ESR2ALOX5 | |
| SCHEMBL6733479 | 0.87 | PTGS2 (0.41) | PTGS2PTGS1ESR1ESR2ALOX5 | |
| SCHEMBL6722665 | 0.85 | PTGS2 (0.40) | PTGS2PTGS1ESR1ESR2ALOX5 | |
| SCHEMBL6723345 | 0.85 | ESR1 (0.44) | PTGS2PTGS1ESR1ESR2ALOX5 | |
| SCHEMBL6723408 | 0.85 | BRAF (0.49) | PTGS2PTGS1ESR1ESR2ALOX5 | |
| SCHEMBL6730003 | 0.85 | ESR1 (0.41) | PTGS2PTGS1ESR1ESR2ALOX5 | |
| SCHEMBL6723168 | 0.85 | ESR1 (0.41) | PTGS2PTGS1ESR1ESR2ALOX5 | |
| SCHEMBL6722772 | 0.84 | MAPK14 (0.47) | PTGS2ESR1ESR2ALOX5MAPK14 | |
| SCHEMBL6721412 | 0.84 | MAPK14 (0.47) | PTGS2PTGS1ESR1ESR2ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040092552-A1 | 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation | PHARMACIA CORPORATION | 2004-05-13 | — | — | US | disclosed |
| US-20020183362-A1 | 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation | PHARMACIA CORPORATION | 2002-12-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020183362-A1 | 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation | FPR2, FPR1, PTGES2 | PTGS2 5/4885PTGS1 4/4885ESR1 1770/4885 |
| US-20040092552-A1 | 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation | FPR2, PTGES2, FPR1 | PTGS2 5/4885PTGS1 4/4885ESR1 1900/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.